Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes
Sponsored by Exsulin Corporation
About this trial
Last updated 11 years ago
Study ID
2003069
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
Yes
Accepting
35 to 70 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 21 years ago
What is this trial about?
Insulin is a chemical that the body needs in order to use or store sugar. It is made by a
type of cell called a beta cell which resides in an organ known as the pancreas. Type 2
diabetes is a disease where the beta cells are unable to meet a person's insulin needs. Sugar
levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new
beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic
patients.
What are the participation requirements?
Inclusion Criteria
- Age 35-70
- Using >20 Units of insulin per day
- HbA1c from 6.5% to 10%
- No islet antibodies
- Otherwise healthy